Evidence map›Paper›PMID 39865818›Full record

ReviewPharmaceutical nanotechnology2026

Unraveling the Mysteries of Brain Cancer from Diagnosis to Treatment.

Dyandevi Mathure, Sejal Bhandare, Dipanjan Karati, Mohammad Adnan, Dileep Kumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dyandevi MathureDepartment of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Pune, India.
Sejal BhandareDepartment of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Pune, India.
Dipanjan KaratiDepartment of Pharmacy, School of Pharmacy, Techno India University-West Bengal, Kolkata, 700091, India.
Mohammad AdnanDepartment of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Pune, India.
Dileep KumarDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even with recent advancements in surgery and multimodal adjuvant therapy, brain cancer treatment is still difficult. The blood-brain barrier and the potentially deadly medications' nonspecificity have made pharmacological treatment for brain cancer particularly ineffective. The nanoparticle has surfaced as a viable brain delivery vector that can solve the issues with existing approaches. Furthermore, it is possible to integrate many functions into a single nanoplatform to enable tumor-specific diagnosis, therapy, and follow-up observation. Conventional technology does not allow for such multitasking. Recent developments in brain cancer treatment and detection using nanoparticles are discussed in this study. The benefits of delivery via nanoparticles are discussed, along with the kinds of nanoparticle systems being studied and their potential uses.

Indexed as

Antineoplastic AgentsBrain NeoplasmsNanoparticlesAnimalsBlood-Brain BarrierDrug Delivery SystemsHumansAntineoplastic Agentsblood-brain barrierBrain cancerchemotherapydual targetingnanotechnologypolymers

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.